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OsteoarthritisInterleukin-1β (IL-1β), a key-cytokine in osteoarthritis, impairs TGFβ signaling through TβRII down-
regulation by increasing its degradation. Here, we investigated the molecular mechanism that controls
TßRII fate in IL-1ß treated cells.
Chondrocytes were treated with IL-1ß in the presence of different inhibitors. TßRII and Cav-1 expression
were assayed by Western blot and RT-PCR.
We showed that IL-1ß-induced degradation of TßRII is dependent on proteasome and on its internalization in
caveolae. In addition, IL-1ß enhances Cav-1 expression, a major constituent of lipid raft.
In conclusion, we enlighten a new mechanism by which IL-1ß antagonizes TGFß pathway and propose a
model of TßRII turnover regulation upon IL-1ß treatment.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Articular cartilage has a very limited capacity of repair, resulting in
progressive and irreversible degradation of this tissue, and subse-
quently osteoarthritis. This tissue is composed of single cell type ,
named chondrocytes, which synthesize an abundant extracellular
matrix, containing a network of collagen ﬁbers (mainly composed of
type II collagen), and proteoglycans (aggrecan). In osteoarthritis car-
tilage, chondrocytes undergo modiﬁcations of their phenotype. In
particular, they change their expression proﬁle, notably of transform-
ing growth factor ß receptors and collagens. Interleukin-1ß, a proin-
ﬂammatory cytokine which is increased during osteoarthritis, is
known to contribute to these processes [1].
Transforming growth factor ß1 (TGFß1) is a major cytokine that
regulates the anabolic process of articular cartilage. It induces its sig-
nal through activation of type I (TßRI) and type II (TßRII) receptors.
These receptors play a major role in osteoarthritis (OA) [2,3]. Their
expression as well as their membrane compartmentalization regu-
lates TGFß1 signaling [4–6]. However, while regulation of their ex-
pression is well documented, little is known about mechanisms
which govern their localization and degradation.
They reside in both lipid raft and non-raft membrane domains [4].
Their internalization by classical clathrin-dependent pathway or raft-ent Cellulaire et Pathologies/
ormandie, 14032 CAEN Cedex,
é).
rights reserved.caveolin route facilitates Smad activation or mediates receptor degra-
dation, respectively [4]. Caveolae are vesicular invaginations of the
plasma membrane formed from a local accumulation of cholesterol,
glycosphingolipids and caveolin-1 (Cav-1). Cav-1 is found in hyaline
cartilage, and more abundantly in OA tissues. Its knock-out leads to
abnormal hyaline cartilage morphology and abnormal chondrocyte
physiology [7]. Besides, Cav-1 suppresses TGFß-mediated transcrip-
tional activation by interacting with TßRI [8].
Recent reports have highlighted cross-talk between TGFß and IL-
1ß in chondrocytes, with IL-1ß playing a role in the negative regula-
tion of TGFß signaling. In particular, IL-1ß reduces TßRII expression
by enhancing its degradation rate [9]. However, the molecular mech-
anism that controls TßRII decay in IL-1ß treated cells is totally un-
known. The aim of this study was to examine the role of TßRII
partitioning and ubiquitin/proteasome pathway on the regulation of
TßRII expression by IL-1ß.
2. Materials and methods
2.1. Reagents
Reagentswere provided by Invitrogen (Cergy Pontoise, France) un-
less otherwise noted. Human recombinant IL-1β (Sigma-Aldrich Co.,
St. Quentin Fallavier, France)was dissolved in PBS-BSA. Cycloheximide
(Sigma), nystatin (Calbiochem-VWR, Fontenay sous Bois, France.),
bortezomib (PS-341), and leupeptin (Roche, Meylan, France) were
resuspended in PBS or DMSO. Antibodies were obtained from Santa
Cruz Biotechnology (TeBU-bio SA, Le Perray en Yvelines, France).
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Human cartilage was obtained from the femoral heads of 15 pa-
tients who underwent hip replacement (ages between 52 and
82 years with median age of 75). Chondrocytes were released and
cultured as previously described [9]. They were ampliﬁed in 10%FCS-
DMEM. Then, cells were kept for 24 h in 2% FCS-containingmedium be-
fore treatment, which was performed in 2%FCS-medium.2.3. Protein extraction and Western blot
Proteins (cytoplasmic, membrane and nuclear) were extracted
using RIPA buffer (150 mM NaCl, 1.0% IGEPAL® CA-630, 0.5%
sodium deoxycholate, 0.1% SDS, and 50 mM Tris, pH 8.0), and West-
ern blot experiments were performed as previously described [9].IL-1β - - + - +
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Fig. 1. Bortezomib counteracts the increase of TβRII turnover induced by IL-1ß.HACs were cultu
FCS for 24 h. Thereafter, they were treated with IL-1β (1 ng/ml) together with cycloheximid
(B) or ammonia chloride (20 mM) (C). Then, proteins were extracted and TβRII expression w
mean of values relative to control, and SD of three experiments. ***Pb0.001; **Pb0.01; *PbDensitometric analyses were performed with ImageJ software, and
histograms represent ratio between TβRII and βactin.
2.4. RNA isolation and real-time RT-PCR
Total RNA was extracted using Trizol reagent and their integ-
rity was checked by migration on agarose gel. Reverse transcrip-
tion and real-time PCR were performed as previously described
[9]. The relative expression was calculated with the 2−ΔΔCT
method.
2.5. Statistical analysis
All experiments were repeated at least three times, each with
different donors. Data are presented as means±SD. Statistical
signiﬁcance was determined by Student's t-test. Differences wereTβ
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Fig. 2.Nystatin counteracts the IL-1ß-induced degradation of TβRII.HACs were cultured
as Fig. 1. Then, they were treated with IL-1β (1 ng/ml) together with cycloheximide
(10 μg/ml) for 7 h in the presence of nystatin (50 μg/ml) and cholesterol (25 μg/ml).
Then, proteins were extracted and TβRII expression was analyzed by Western blot
and quantiﬁed by densitometry. Histograms represent the mean of values relative to
control, and SD of three experiments. ***Pb0.001; **Pb0.01; *Pb0.05 versus controls.
NS: no signiﬁcant difference.
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Fig. 3. IL-1β increases Cav-1 expression.HACs were incubated in DMEM+2% FCS for
24 h, before addition of IL-1β (1 ng/ml) or vehicle (control) for indicated times.
mRNA levels of caveolin-1 gene were assayed by real-time RT-PCR. Results are
shown as histograms of relative expression versus GAPDH signal (A). Similarly, HACs
were treated with IL-1β (1 ng/ml) for 48 h. Then, proteins were extracted and Cav1
expression was analyzed by Western blot (B).
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3. Results
3.1. IL-1β-induced degradation of TβRII is reduced by proteasome and
lysosome inhibitors
Proteolysis of membrane receptor, such as TGFß receptors, is me-
diated by both the proteasome and lysosome. To test whether the en-
hanced degradation of TßRII upon IL-1ß treatment occurred through
proteasome pathway, we assessed TßRII turnover in the presence of
bortezomib, a proteasome inhibitor. TβRII levels were very similar
with and without proteasome inhibitor, but in the presence of IL-
1β, bortezomib leaded a signiﬁcant difference. This treatment totally
counteracted the increase of TβRII turnover induced by IL-1ß
(Fig. 1A), indicating that IL-1ß induced degradation of TßRII is depen-
dent on proteasome pathway.
Similarly, TßRII degradation induced by IL-1ß was evaluated in
cells treated with leupeptin or ammonia chloride, two inhibitors of ly-
sosomal degradation. Surprisingly, under cycloheximide, leupeptin
induced TßRII degradation whereas ammonium chloride treatments
reduced it. Interestingly, both treatments reduced the IL-1ß induced
degradation (Fig. 1B and C). These experiments indicate that TßRII
degradation induced by IL-1ß is dependent on proteasome and im-
paired by lysosome inhibitors.
3.2. IL-1β-induced degradation of TβRII is dependent on caveola
trafﬁcking
To evaluate the importance of the trafﬁcking of TGFß receptors
via the lipid raft in decay of the receptor upon IL-1ß treatment,
we followed the degradation of TßRII in cells incubated with nys-
tatin, which induces depletion of membrane-associated cholesterol
and consequently disruption of both lipid rafts and caveolae
whereas it does not interfere with clathrin-dependent endocytosis
[4]. Nystatin, by itself, did not affect TβRII degradation (lanes 2, 4,
and 6). However, in the presence of IL-1β, it counteracted TßRII
degradation (lanes 3–5). This effect was dependent on chelation
of cholesterol, as the addition of cholesterol to nystatin-treated
cells restored receptor turnover in the presence of IL-1ß (lanes
6–7) (Fig. 2).
3.3. IL-1β increases caveolin-1 expression
Since receptor trafﬁcking may be modulated by caveolin-1 expres-
sion, we investigated Cav1 expression in IL-1ß-treated chondrocytes.
Fig. 3 shows that caveolin-1 mRNA level is increased by IL-1ß. This
effect appeared as soon as 1 h of incubation and persisted for at
least 72 h. Therefore, we investigated Cav1 protein level by Western
Blot. Again, as at mRNA level, we found that IL-1ß increases Cav1
protein expression.
4. Discussion
This paper enlightens a new mechanism by which IL-1ß downre-
gulates TßRII expression in human chondrocytes. We show that IL-
1ß increases TßRII decay through receptor-mediated endocytosis by
raft lipid and proteasomal pathway. Interestingly, intra-articular in-
jections of MG132, a proteasome inhibitor, signiﬁcantly reduces OA
lesions in animal OA model [10]. So, our study may explain part of
the protective effect of MG132.
Since degradation of proteins by the proteasome pathway is de-
pendent on their ubiquitination, the regulation of TßRII degradation
might involve speciﬁc E3 ubiquitin ligases. Among them, Smurf2
is interesting. It opposites to TGFß signal in inducing mediatorsdegradation through ubiquitin/proteasome pathway [11,12]. In par-
ticular, Smurf2 is able to interact with Smad7 which functions as an
adaptor protein that recruits Smurf2 to the activated TGFβ receptor
complex to promote its degradation [12]. It also negatively regu-
lates TGF-β signaling by attenuating the activity of Smad3 [13]. Ad-
ditionally, Smurf2 is up-regulated during OA, and Smurf2-
transgenic mice spontaneously develop an OA-like phenotype,
which is similar to transgenic mice that express a dominant-
negative mutant of TβRII [11,3].
Another candidate is NEDD4 family, which is known to nega-
tively regulate TGF-beta superfamily signaling [14]. Of interest,
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proliferating and prehypertrophic chondrocytes [16]. So, since
TßRII degradation depends on trafﬁc in lipid rafts, we suggest
that Nedd4 family members could be responsible of this phenom-
ena. Further experiments will be required to determine which E3
ubiquitin ligase is involved.
Concerning the putative role of lysomal degradation, our exper-
iments cannot permit to deﬁnitively conclude. Indeed, in the pres-
ence of leupeptin and ammonium chloride, two lysosomotropic
agents, we observed a reduction of the IL-1ß induced degradation
suggesting that this pathway may be involved in the degradation
of TßRII induced by IL-1ß. However, we cannot exclude an indirect
action of these lysosomal inhibitors on proteasome. Indeed, inhibi-
tion of lysosomal functions reduces proteasomal activity [17]. In
addition, we found a differential effect of these lysosomotropic
agents. NH4Cl reduced TβRII degradation, whereas leupeptin in-
creased it. This differential effect on receptor degradation (without
IL-1β treatments) may be due to differential functions of these in-
hibitors. Indeed, NH4Cl affected the endosomal and lysosomal com-
partments, whereas leupeptin had a preferential effect on
lysosomes [18]. Further experiments will be required to better
characterize the role of endosome/lysosome pathways. Moreover,
in this study, we used protein extracts obtained from cell lysis
with Ripa buffer. Consequently, we analyzed the global level of
TβRII (present in cytoplasmic, nuclear and membrane fractions)
and not the membrane fraction of the receptor. Using membrane
extracts, and subcellular fractionation techniques may be useful to
improve our understanding of the mechanisms of TβRII internaliza-
tion and degradation.
In agreement with observations of Veluthakal and colleagues, who
indicate a signiﬁcant translocation of Cav-1 into Cav-1 rich compart-
ments from isolated cells after brief exposure to IL-1ß [19], we estab-
lished that IL-1ß enhances Cav-1 expression. This induction of Cav-1
could promote TßRII trafﬁc in lipid raft and subsequently increase
the turnover of this receptor upon IL-1ß treatment. In this regard,
similarly to TßRI, TßRII may physically interact with Cav-1. Indeed,
TßRII cofractionates with caveolin-1 in caveola enriched-
microdomains [7]. This Cav1/TßRII interaction could presumably
occur via the TßRII serine/threonine kinase domain, because func-
tional caveolin-binding motifs have been deduced in this domain
[20]. Furthermore, consistent with our hypothesis, expression ectopic
of caveolin-1 reduces TGFß receptors half-life by cooperating with
Smad7-Smurf2 [4].
Together, our data permits us to propose a model of control
TßRII decay by IL-1ß. We suggest that IL-1ß increases caveolin-1
expression, leading the internalization of TßRII in lipid raft and
subsequently its degradation by the proteasome. Additionally, in-
ternalization in lipid raft could be promoted by a physically inter-
action between IL-1 receptor and TßRII in complex named
“receptosome” which was described by Stark's group [21]. Associ-
ation of the two types of receptors might trigger cross-talk in
two signaling pathways. A similar mechanism by which turnover
is regulated by interaction between distinct receptor populations
on the cell surface (CD44 and TGFß receptors) has been previously
described [5].
In conclusion, we enlightened a new mechanism by which IL-1ß
downregulates TßRII expression. We bring evidence that IL-1ß is
able to reduce TGFß function through TßRII protein destabilization
occurring through receptor-mediated endocytosis by raft lipid and
proteasomal pathway.
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